| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-At Market Offering | 15,020,046 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Warrant | 24,998,919 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Public Offering | 164,500,006 | - |
| Proceeds from issuance of common stock under at-the-market offering, net of offering expenses | - | 13,676,667 |
| Proceeds from issuance of common stock through private placement with aventis inc | 25,000,000 | - |
| Payment of offering and placement costs | 3,138,911 | 64,013 |
| Net cash provided by financing activities | 226,940,670 | 13,748,601 |
| Net increase (decrease) in cash and cash equivalents | 191,418,357 | -9,789,222 |
| Cash and cash equivalents at beginning of period | 36,144,720 | - |
| Cash and cash equivalents at end of period | 227,563,077 | - |
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)